Review
doi: 10.1152/physiol.00030.2005.
Proglucagon-derived peptides: mechanisms of action and therapeutic potential
Affiliations
- PMID: 16174875
- DOI: 10.1152/physiol.00030.2005
Item in Clipboard
Review
Proglucagon-derived peptides: mechanisms of action and therapeutic potential
Physiology (Bethesda).
2005 Oct.
Free article
Abstract
Glucagon is used for the treatment of hypoglycemia, and glucagon receptor antagonists are under development for the treatment of type 2 diabetes. Moreover, glucagon-like peptide (GLP)-1 and GLP-2 receptor agonists appear to be promising therapies for the treatment of type 2 diabetes and intestinal disorders, respectively. This review discusses the physiological, pharmacological, and therapeutic actions of the proglucagon-derived peptides, with an emphasis on clinical relevance of the peptides for the treatment of human disease.
Similar articles
-
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.
-
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter.Regul Pept. 2005 Jun 15;128(2):97-107. doi: 10.1016/j.regpep.2004.08.026. Regul Pept. 2005. PMID: 15780429 Review.
-
Minireview: the glucagon-like peptides.Endocrinology. 2001 Feb;142(2):521-7. doi: 10.1210/endo.142.2.7983. Endocrinology. 2001. PMID: 11159819 Review.
-
Biologic actions and therapeutic potential of the proglucagon-derived peptides.Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):22-31. doi: 10.1038/ncpendmet0017. Nat Clin Pract Endocrinol Metab. 2005. PMID: 16929363 Review.
-
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.Curr Opin Pharmacol. 2004 Dec;4(6):589-96. doi: 10.1016/j.coph.2004.08.005. Curr Opin Pharmacol. 2004. PMID: 15525549 Review.
Cited by
-
Relationship between gut hormones and glucose homeostasis after bariatric surgery.Diabetol Metab Syndr. 2014 Aug 16;6(1):87. doi: 10.1186/1758-5996-6-87. eCollection 2014. Diabetol Metab Syndr. 2014. PMID: 25152774 Free PMC article. Review.
-
Paying the price for eating ice cream: is excessive GLP-1 signaling in the brain the culprit?Endocrinology. 2008 Oct;149(10):4765-7. doi: 10.1210/en.2008-0932. Endocrinology. 2008. PMID: 18809947 Free PMC article. No abstract available.
-
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.BMJ Open Gastroenterol. 2021 May;8(1):e000604. doi: 10.1136/bmjgast-2021-000604. BMJ Open Gastroenterol. 2021. PMID: 33975891 Free PMC article.
-
A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity.Nat Commun. 2023 Mar 14;14(1):1405. doi: 10.1038/s41467-023-36946-7. Nat Commun. 2023. PMID: 36918550 Free PMC article.
-
Type 2 diabetes mellitus: a possible surgically reversible intestinal dysfunction.Obes Surg. 2012 Jan;22(1):167-76. doi: 10.1007/s11695-011-0563-2. Obes Surg. 2012. PMID: 22094369 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
